Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
This randomized phase III trial studies ipilimumab to see how well it works compared to high-dose interferon alfa-2b in treating patients with high-risk stage III-IV melanoma that has been removed by surgery. Monoclonal antibodies, such as ipilimumab, may interfere with the ability of tumor cells to grow and spread. Interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of melanoma and other cancers. It is not yet known whether ipilimumab is more effective than interferon alfa-2b in treating patients with melanoma.
This research study is led by Dr. John McCann.
Contact: Dawn DeMarinis, 413-795-4362
May 25, 2011
Cancer - Melanoma
D’Amour Center for Cancer Care, 3350 Main Street, Springfield, MA
Ages Eligible for Study: 12 Years and older (Child, Adult, Older Adult)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Interventional (Clinical Trial), Randomized